Amarin Corporation

Amarin Corporation CROIC

The Cash Return on Invested Capital (CROIC) of Amarin Corporation (AMRN) as of Nov 19, 2026 is 1.43 %. In the previous year, Cash Return on Invested Capital (CROIC) was -6.28 % — a change of -122.78% (higher).

CROIC

1.43 %

YoY

-122.78%

Last updated:

Cash Return on Invested Capital (CROIC) of Amarin Corporation is 2025 1.43 % . Cash Return on Invested Capital (CROIC) of Amarin Corporation was 2024 -6.28 % . It decreases by -122.78% higher compared to the previous year.

The Amarin Corporation CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-40.73 USD
Jan 1, 2019
-1.77 USD
Jan 1, 2020
-3.46 USD
Jan 1, 2021
-9.85 USD
Jan 1, 2022
-29.73 USD
Jan 1, 2023
1.23 USD
Jan 1, 2024
-6.28 USD
Jan 1, 2025
1.43 USD
The Amarin Corporation CROIC history
YEARCROICYoY
1.43 %-122.78%
-6.28 %-611.78%
1.23 %-104.13%
-29.73 %+201.96%
-9.85 %+184.97%
-3.46 %+94.83%
-1.77 %-95.65%
-40.73 %-28.64%
-57.07 %-14.68%
-66.89 %-3.76%
-69.51 %+32.99%
-52.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Cash Return on Invested Capital (CROIC) of Amarin Corporation is 1.43 % in 2025.

Cash Return on Invested Capital (CROIC) of Amarin Corporation changed from -6.28 % to 1.43 %, representing a -122.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Amarin Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Amarin Corporation

All Key Metrics — Amarin Corporation